Navigation Links
B. Braun to Showcase Its Safety-Engineered IV Therapy Portfolio at INS
Date:11/4/2013

BETHLEHEM, Pa., Nov. 4, 2013 /PRNewswire/ -- B. Braun Medical Inc. (B.Braun) will sponsor an exhibit theater presentation at the Infusion Nursing Society (INS) Fall National Academy of Infusion Therapy convention in Boston, MA, November 8th-10th. The presentation, "Navigating the Depths: Ultrasound Guided Short PIV Insertions—Implications and Limitations for Practice," will feature a discussion of technology and procedures related to utlrasound guided peripheral IV insertion that highlights standardized approaches to patient assessment and techniques for vessel access.

Dr. Robert B. Dawson, DNP, MSA, APRN, ACNP--BC, CPUI, CRNI, VA-BC, Vascular Access Consultant, PICC Academy, will be the featured presenter. The presentation will take place on Saturday, November 9, 2013 from 11:10 am-12:00 p.m. at the Exhibitor Theater in the Industrial Exhibition Room, Galleria Hall.   

Click here for an audio Podcast presentation preview of Robert Dawson.

Catheter-related bloodstream infections (CRBSIs), needlestick (sharps) injuries and exposure to potentially deadly blood borne pathogens continue to be major issues facing all healthcare professionals. 

"B.Braun is passionately committed to combating these issues by providing safety-engineered IV therapy devices that offer patient protection against infection and optimum safety for clinicians in the workplace," said Tom Sutton, Vice President of Vascular Access Systems at B.Braun.

B.Braun will demonstrate the following safety-engineered IV therapy devices at booth (#16) during INS:   


SOURCE B. Braun Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. B. Braun Purchases Land To Build New North American Headquarters
2. B. Braun Signs U.S. Distributor Agreement for Dialysis Water Purification Systems
3. B. Braun Receives FDA Approval For New Large-Volume Irrigation Containers
4. B. Braun Receives FDA Approval For New Large-Volume Intravenous Containers
5. B. Braun to Showcase Its Safety-Engineered IV Therapy Portfolio at AVA
6. B. Braun Awarded Premier Healthcare Alliance Contract for Dual-Source IV
7. Patient and Healthcare Worker Safety Major Areas of Focus at B.Braun
8. B. Braun Smart Infusion Pump Technology to be Featured in Integrating the Healthcare Enterprise (IHE) Interoperability Demonstration at AAMI 2013
9. B. Braun Committed To Improving Patient Safety
10. B. Braun Reveals Customer Satisfaction Survey
11. B. Braun Committed to Protecting Healthcare Workers from Exposure to Hazardous Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission ... ResMed (RMD) against BMC Medical. In a notice issued on ... found that ResMed,s patent on its humidifier was invalid. ... a "monumental win". "We are very excited with the ITC,s ... position that we have taken since the very beginning on ...
(Date:12/24/2014)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ), the ... Jennifer Hagerman , Pharm.D., AE-C, senior director of ... the president of the Michigan Pharmacists Association on Jan. ... Feb. 28, 2015, at the MPA Annual Convention and ... in Detroit, Michigan . Hagerman will ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3
... Aug. 21 Genetic testing can be,used to ... anticoagulant, according to research published in the,September 1, ... American Society of,Hematology. This result represents one of ... to guide personal medical care., Because individuals ...
... Randomized, Double-Blind Study Targets Biomarker-Defined Population, ... (Nasdaq: GNTA ) announced that the ... confirmatory Phase 3 trial of Genasense,(oblimersen sodium) ... as,AGENDA, is a randomized, double-blind, placebo-controlled study ...
Cached Medicine Technology:Genetics Determine Optimal Drug Dose of Common Anticoagulant 2Genetics Determine Optimal Drug Dose of Common Anticoagulant 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5
(Date:12/26/2014)... (PRWEB) December 26, 2014 Yisrayl Hawkins, Pastor ... an open letter in light of the Ferguson, Missouri unrest. ... of civil unrest and explains why it has only increased. ... mankind was even created. He says there is a very ... Yisrayl also says there is a set of rules, or ...
(Date:12/26/2014)... Orlando, FL (PRWEB) December 26, 2014 ... visitor health insurance in the USA, announced today a ... to assist members in choosing the right plan for ... take the complexity out of the selection process when ... premiums by age group with only a few clicks. ...
(Date:12/25/2014)... The microscopy market is estimated to grow ... million by 2019. Optical microscopy is the largest ... product segment is expected to show the fastest ... on nanotechnology, technological advancements, and increasing federal support ... Get Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... June 6 The makers of the WaveSense(TM),line of ... the WaveSense Presto and WaveSense KeyNote Pro Blood Glucose,Monitoring ... with premium,features that consumers can buy at a value ... with added features for increased safety., The Presto ...
... University of Cincinnati (UC), says that cases of Amyotrophic ... first Persian Gulf War were caused by certain events ... exposure and illness is not as widespread as previously ... July issue of Neuroepidemiology. , Ronnie Horner, PhD, lead ...
... Carriage Services, Inc.,(NYSE: CSV ) today announced ... which can be found on Carriage,s website at, ... Profile includes updated,discussions of Carriage,s business, operating and ... The Company & Investment Profile is being ...
... part of its,ongoing efforts to alleviate human ... and Development (LIFE), recently shipped an,entire forty-foot ... Somalia., In partnership with California-based RICE ... Agency for the Horn,of Africa (ARAHA), two ...
... Grubb & Ellis,Healthcare REIT, Inc. today announced ... consisting of 22 office condominiums in,the Manchester-suburb of ... Nutfield Professional Center consists of,approximately 70,000 square feet ... Center was renovated in 1990 and again in ...
... 5 joint statement, the,presiding bishops of the Evangelical Lutheran ... citizens to pray for peace in Sudan, and,they called ... there., The Rev. Mark S. Hanson of the ... Church made their comments in a public statement,following a ...
Cached Medicine News:Health News:New WaveSense Presto(TM) and Pro(TM) Glucose Meters to Simplify Testing 2Health News:UC research shows risk of ALS exposure in Gulf War veterans is time limited 2Health News:Carriage Services Updates Company & Investment Profile 2Health News:Grubb & Ellis Healthcare REIT Acquires Nutfield Professional Center in Derry, N.H. 2Health News:Grubb & Ellis Healthcare REIT Acquires Nutfield Professional Center in Derry, N.H. 3Health News:Lutheran, Episcopal Church Presiding Bishops Urge Prayers for Peace in Sudan 2
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... Vitros 250 is a flexible ... in multiple environments small ... clinics and satellite locations. The ... dilution, and can be automated ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
Medicine Products: